Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.

Details

Serval ID
serval:BIB_30851676B0A7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Journal
Cytotherapy
Author(s)
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T., Rusakiewicz S., Rossier L., Boudousquié C., Baumgaertner P., Zimmermann S., Trueb L., Iancu E.M., Sempoux C., Demartines N., Coukos G., Kandalaft L.E.
ISSN
1477-2566 (Electronic)
ISSN-L
1465-3249
Publication state
Published
Issued date
12/2020
Peer-reviewed
Oui
Volume
22
Number
12
Pages
780-791
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Several studies report on Good Manufacturing Process (GMP)-compliant manufacturing protocols for the ex vivo expansion of tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory melanoma and other solid malignancies. Further opportunities for improvements in terms of ergonomy and operating time have been identified.
To enable GMP-compliant TILs production for adoptive cell therapy needs, a simple automated and reproducible protocol for TILs manufacturing with the use of a closed system was developed and implemented at the authors' institution.
This protocol enabled significant operating time reduction during TILs expansion while allowing the generation of high-quality TILs products.
A simplified and efficient method of TILs expansion will enable the broadening of individualized tumor therapy and will increase patients' access to state-of-the-art TILs adoptive cell therapy treatment.
Keywords
Good Manufacturing Practice (GMP), Swissmedic, adoptive cell therapy (ACT), immunotherapy, manufacturing, tumor-infiltrating lymphocytes (TILs)
Pubmed
Web of science
Create date
20/10/2020 12:42
Last modification date
06/01/2021 6:25
Usage data